Wei Zhiyuan, Wang Jiangbin
Department of Digestive, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Front Immunol. 2024 Apr 18;15:1375654. doi: 10.3389/fimmu.2024.1375654. eCollection 2024.
Inflammatory bowel disease (IBD) is often associated with complex extraintestinal manifestations. The incidence of nonalcoholic fatty liver disease (NAFLD) in IBD populations is increasing yearly. However, the mechanism of interaction between NAFLD and IBD is not clear. Consequently, this study aimed to explore the common genetic characteristics of IBD and NAFLD and identify potential therapeutic targets.
Gene chip datasets for IBD and NAFLD were obtained from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was performed to identify modules in those datasets related to IBD and NAFLD. ClueGO was used for biological analysis of the shared genes between IBD and NAFLD. Based on the Human MicroRNA Disease Database (HMDD), microRNAs (miRNAs) common to NAFLD and IBD were obtained. Potential target genes for the miRNAs were predicted using the miRTarbase, miRDB, and TargetScan databases. Two-sample Mendelian randomization (MR) and two-way MR were used to explore the causal relationship between Interleukin-17 (IL-17) and the risk of IBD and NAFLD using data from GWAS retrieved from an open database.
Through WGCNA, gene modules of interest were identified. GO enrichment analysis using ClueGO suggested that the abnormal secretion of chemokines may be a common pathophysiological feature of IBD and NAFLD, and that the IL-17-related pathway may be a common key pathway for the pathological changes that occur in IBD and NAFLD. The core differentially expressed genes (DEGs) in IBD and NAFLD were identified and included COL1A1, LUM, CCL22, CCL2, THBS2, COL1A2, MMP9, and CXCL8. Another cohort was used for validation. Finally, analysis of the miRNAs identified potential therapeutic targets. The MR results suggested that although there was no causal relationship between IBD and NAFLD, there were causal relationships between IL-17 and IBD and NAFLD.
We established a comorbid model to explain the potential mechanism of IBD with NAFLD and identified the chemokine-related pathway mediated by cytokine IL-17 as the core pathway in IBD with NAFLD, in which miRNA also plays a role and thus provides potential therapeutic targets.
炎症性肠病(IBD)常伴有复杂的肠外表现。IBD人群中非酒精性脂肪性肝病(NAFLD)的发病率逐年上升。然而,NAFLD与IBD之间的相互作用机制尚不清楚。因此,本研究旨在探索IBD和NAFLD的共同遗传特征,并确定潜在的治疗靶点。
从基因表达综合数据库(GEO)获取IBD和NAFLD的基因芯片数据集。进行加权基因共表达网络分析(WGCNA)以识别这些数据集中与IBD和NAFLD相关的模块。ClueGO用于对IBD和NAFLD之间的共享基因进行生物学分析。基于人类微小RNA疾病数据库(HMDD),获取NAFLD和IBD共有的微小RNA(miRNA)。使用miRTarbase、miRDB和TargetScan数据库预测这些miRNA的潜在靶基因。利用从开放数据库检索到的全基因组关联研究(GWAS)数据,采用两样本孟德尔随机化(MR)和双向MR来探索白细胞介素-17(IL-17)与IBD和NAFLD风险之间的因果关系。
通过WGCNA,确定了感兴趣的基因模块。使用ClueGO进行的基因本体(GO)富集分析表明,趋化因子的异常分泌可能是IBD和NAFLD的共同病理生理特征,且IL-17相关通路可能是IBD和NAFLD发生病理变化的共同关键通路。确定了IBD和NAFLD中的核心差异表达基因(DEG),包括COL1A1、LUM、CCL22、CCL2、THBS2、COL1A2、MMP9和CXCL8。使用另一个队列进行验证。最后,对miRNA的分析确定了潜在的治疗靶点。MR结果表明,虽然IBD和NAFLD之间没有因果关系,但IL-17与IBD和NAFLD之间存在因果关系。
我们建立了一个共病模型来解释IBD合并NAFLD的潜在机制,并确定细胞因子IL-17介导的趋化因子相关通路是IBD合并NAFLD的核心通路,其中miRNA也发挥作用,从而提供了潜在的治疗靶点。